Hosted on MSN9mon
FDA approves Takeda’s ENTYVIO SC for Crohn’s disease
The US Food and Drug Administration (FDA) has granted approval for Takeda’s ENTYVIO subcutaneous (SC) administration as a maintenance therapy to treat adults with moderately to severely active ...
pharmaphorum1y
Takeda tries again with subcutaneous Entyvio
More than three years after it was first rejected by the FDA, Takeda's subcutaneous (SC) formulation of Entyvio has been resubmitted as a maintenance therapy for ulcerative colitis. The new ...
Hosted on MSN11mon
Polpharma looks to challenge Takeda’s Entyvio in IBD
Takeda has also invested in sustaining and increasing revenue generated by Entyvio. The company developed a subcutaneous formulation of the monoclonal antibody, which was approved by the US FDA as ...